CXCL12 and systemic lupus erythematosus: Ameliorates the histopathological changes in a murine model of SLE. Significantly increases plasma levels of IL-4, IL-6, IL-7, IL-12, IL-17, IFN-α, IFN-γ, TGF-β, BAFF, and APRIL and markedly increases IgG2a, IgG3, and anti-dsDNA autoantibodies. Attenuates B cell autoreactivity by modulating the CXCL12/CXCR4 axis and its downstream signals PI3K/AKT, NFκB, and Erk.